Point72 Hong Kong LTD Argenx Se Transaction History

Point72 Hong Kong LTD

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	BUY	$356.01 - $451.55 $63,369 - $80,375	178 New	178 $76,000
Q3 2020 Nov 16, 2020	SELL	$215.51 - $272.51 $1,508 - $1,907	-7 Closed	0 $0
Q4 2018 Feb 14, 2019	BUY	$63.81 - $109.82 $446 - $768	7 New	7 $1,000
Q3 2018 Nov 14, 2018	SELL	$75.5 - $96.63 $528 - $676	-7 Closed	0 $0
Q1 2018 May 15, 2018	BUY	$56.95 - $85.19 $398 - $596	7 New	7 $1,000

400

30.9M

376K

489K

Ticker ARGX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 55,323,800
Market Cap $34.8B
Description
argenx SE, a biotechnology company, focuses on developing various therapies for the treatment of autoimmune diseases in the United States, the Netherlands, Belgium, Japan, Switzerland, Germany and France. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, ...

Get notified when there are updates to the investment portfolio of Point72 Hong Kong LTD, based on Form 13F filings with the SEC.

Stay updated on Point72 Hong Kong LTD with notifications on news.